Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.08 USD | -0.84% | -2.34% | +4.89% |
18/03 | Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer | MT |
18/03 | Fulcrum Therapeutics, Inc. Announces Executive Changes | CI |
Business Summary
Number of employees: 76
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 6 | 100.0 % | 3 | 100.0 % | -55.77% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 3 | 100.0 % | -55.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alex Sapir
CEO | Chief Executive Officer | 57 | 01/23/01 |
Alan Musso
DFI | Director of Finance/CFO | 61 | 07/23/07 |
Chief Tech/Sci/R&D Officer | - | 01/21/01 | |
Leslie Leinwand
CMP | Compliance Officer | - | - |
Chief Tech/Sci/R&D Officer | 61 | 01/22/01 | |
Robert Gould
BRD | Director/Board Member | 69 | - |
Iain Fraser
PRN | Corporate Officer/Principal | - | 01/23/01 |
Kristina Storey
LAW | General Counsel | - | 01/22/01 |
Paul Bruno
PRN | Corporate Officer/Principal | - | 01/19/01 |
Comptroller/Controller/Auditor | - | 11/22/11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Geraghty
BRD | Director/Board Member | 70 | 19/16/19 |
Director/Board Member | 70 | 01/16/01 | |
James Collins
BRD | Director/Board Member | 58 | 01/17/01 |
Robert Gould
BRD | Director/Board Member | 69 | - |
Kathryn Haviland
CHM | Chairman | 48 | 27/18/27 |
Katina Dorton
BRD | Director/Board Member | 66 | 02/20/02 |
Alex Sapir
CEO | Chief Executive Officer | 57 | 01/23/01 |
Sonja L. Banks
BRD | Director/Board Member | 55 | 08/21/08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 62,153,638 | 61,297,958 ( 98.62 %) | 0 | 98.62 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.89% | 444M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- FULC Stock
- Company Fulcrum Therapeutics, Inc.